---
schema_version: "secwatch.filing_event.v1"
accession: "0001411685-25-000048"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2025-06-25T23:59:59+00:00"
generated_at: "2026-05-18T19:10:20.786886+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Vistagen appoints Elissa Cote as Chief Corporate Development Officer

## Summary
- Cote appointed CCDO effective June 23, 2025, to lead strategic partnerships and pherine platform advancement.
- Nearly 30 years biopharma BD experience; previously Chief Strategy/BD Officer at Mallinckrodt Pharmaceuticals.
- Received inducement option for 150,000 shares at June 23 closing price; vests 25% year one, then monthly over 36 months.
- Pipeline includes five intranasal pherine candidates targeting six CNS disorders.

## SEC filing metadata
- accession: 0001411685-25-000048
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2025-06-25T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000141168525000048/0001411685-25-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000141168525000048/vtgn-20250623.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001411685-25-000048
- JSON: https://secwatch.observer/filing/0001411685-25-000048.json
- Plain text: https://secwatch.observer/filing/0001411685-25-000048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.